Dayvigo (Lemborexant) Cost in Nebraska 2026: Prices, Insurance, and Savings

What Dayvigo Actually Costs in Nebraska Right Now

The sticker price and the price you pay are rarely the same number. Eisai, the manufacturer of Dayvigo, sets the wholesale acquisition cost (WAC) at $320 per month for a 30-tablet supply of either the 5 mg or 10 mg strength. That figure appears on pharmacy shelf tags and prior-authorization paperwork, but most Nebraskans filling a Dayvigo prescription pay less.

Across Nebraska retail pharmacies in 2026, the average cash-pay price for a 30-day supply of Dayvigo is approximately $85 per month. This figure reflects negotiated rates available through discount programs, pharmacy benefit managers, and direct-purchase pricing at major chains operating in Lincoln, Omaha, Grand Island, and smaller communities. The spread between pharmacies can be wide. A single pharmacy in Omaha may charge $70 while a rural independent lists $110 for the same tablet count, so calling ahead or using a price-comparison tool before filling is worth the effort.

Dayvigo received FDA approval in December 2019 as a dual orexin receptor antagonist (DORA) for adults with insomnia characterized by difficulty with sleep onset or sleep maintenance [1]. The approval was supported by the SUNRISE-1 trial (N=1,006), a Phase III randomized, double-blind study that demonstrated lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared with placebo and the older Z-drug zolpidem extended-release 6.25 mg at one month [2].

Nebraska Medicaid Does Not Cover Dayvigo

If you carry Nebraska Medicaid (administered through Heritage Health managed care), Dayvigo is not on the preferred drug list. This means a standard pharmacy claim for lemborexant will be denied at the point of sale.

Nebraska's Medicaid formulary tends to favor older, less expensive insomnia agents. Generic suvorexant (Belsomra), trazodone, and generic zolpidem all appear on the preferred tier. A prescriber can file a prior authorization request arguing clinical necessity for Dayvigo, but approvals for non-preferred branded DORAs remain uncommon when a formulary alternative exists in the same pharmacologic class.

The American Academy of Sleep Medicine (AASM) clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia, and Nebraska Medicaid reviewers often cite this guideline to justify a step-therapy requirement before approving a second DORA [3]. If suvorexant has been tried and failed, or if documented adverse effects prevent its use, documentation of that history strengthens any appeal.

For Nebraskans who qualify for both Medicaid and Medicare (dual-eligible), coverage falls under the Medicare Part D plan, not Medicaid. Part D formularies vary by plan, so dual-eligible patients should check their specific plan's drug list.

Commercial Insurance Coverage Across Nebraska

Most large commercial insurers operating in Nebraska place Dayvigo on a non-preferred brand tier (Tier 3 or Tier 4). Plans from Blue Cross Blue Shield of Nebraska, Medica, and UnitedHealthcare typically require prior authorization and may impose step therapy through a generic sleep agent first.

A Tier 3 copay in Nebraska commonly ranges from $50 to $80 per month, while Tier 4 coinsurance can run 25% to 40% of the negotiated price. The exact amount depends on the plan's benefit design. Patients with high-deductible health plans (HDHPs) pay the full negotiated rate until their deductible is met, which can make the first few months of the year particularly expensive.

Prior authorization criteria across Nebraska commercial plans generally require documentation that the patient has:

• Tried and failed at least one preferred sleep medication (often generic zolpidem or trazodone)
• A diagnosis of insomnia disorder per DSM-5 or ICSD-3 criteria
• No concurrent use of other CNS depressants that would contraindicate a DORA

According to Endocrine Society guidance on sleep and metabolic health, untreated insomnia worsens insulin resistance, cortisol dysregulation, and weight gain, a clinical argument that can support prior authorization appeals for patients with comorbid metabolic conditions [4].

How the Eisai Savings Card Works in Nebraska

Eisai offers a manufacturer copay savings card for commercially insured patients filling Dayvigo prescriptions. The card reduces out-of-pocket costs to as little as $0 per month for eligible patients, with a maximum annual benefit that typically caps at $3,600 per calendar year.

Eligibility requirements are straightforward. You must have commercial insurance (not a government plan). You must be 18 or older. The prescription must be for an FDA-approved indication.

Nebraska patients cannot use the Eisai savings card if they carry Medicare Part D, Medicaid, TRICARE, or any other federally funded program. This restriction is federal law, not an Eisai policy.

To activate the card, patients can enroll online through Eisai's patient support portal or receive an activation code from their prescriber. The card is presented at the pharmacy alongside the insurance card. The pharmacy runs the insurance claim first, then applies the savings card to the remaining copay or coinsurance balance.

One practical note: some Nebraska pharmacies require the savings card to be entered as a secondary BIN/PCN, not as a discount code. If the pharmacy staff is unfamiliar with the process, the Eisai support line can walk them through the claim adjudication steps in real time.

Compounded Lemborexant in Nebraska: Legal Status and Pricing

Compounded lemborexant is available in Nebraska through licensed 503A compounding pharmacies. Under federal law (FDA guidance on 503A compounding), a 503A pharmacy may compound a copy of an FDA-approved drug when it holds a valid patient-specific prescription and operates under a state-licensed pharmacist.

Nebraska's Board of Pharmacy follows the standard 503A framework. A compounding pharmacy in Nebraska can prepare lemborexant capsules if the prescriber writes a patient-specific prescription, the pharmacy sources the active pharmaceutical ingredient (API) from an FDA-registered supplier, and the compound is not essentially a copy produced on a commercial scale.

Pricing for compounded lemborexant varies. Some 503A pharmacies in Nebraska price compounded DORA capsules lower than the brand, though availability depends on API sourcing and individual pharmacy pricing models. Patients considering this route should confirm the pharmacy's 503A license status with the Nebraska DHHS Drug Control Division and ask about beyond-use dating, since compounded capsules may have shorter shelf lives than the manufactured tablet.

Quality control is the main clinical consideration. The SUNRISE-1 trial data supporting Dayvigo's efficacy and safety profile were generated using the manufactured formulation [2]. Compounded versions are not required to undergo bioequivalence testing, so absorption characteristics could differ.

Telehealth Prescribing of Dayvigo in Nebraska

Nebraska permits telehealth prescribing of Schedule IV controlled substances, including Dayvigo. The state adopted provisions under the Ryan Haight Act's telemedicine exception and expanded telehealth access during 2020, with extensions that remain in effect through 2026.

A Nebraska-licensed prescriber (MD, DO, NP, or PA) can evaluate a patient via synchronous audio-video visit and prescribe lemborexant without an in-person exam, provided the prescriber uses their clinical judgment that the evaluation is adequate. The DEA registration must be active and the prescription transmitted electronically to a Nebraska pharmacy.

This matters for cost because telehealth consultations are often less expensive than in-office sleep medicine visits. The CDC's data on insomnia prevalence shows roughly 14.5% of U.S. adults report trouble falling asleep most days, and telehealth has lowered the barrier to treatment for many of these patients, especially in rural western Nebraska where sleep specialists are scarce [5].

HealthRX offers telehealth consultations for insomnia treatment in Nebraska, including evaluation for Dayvigo and other sleep medications.

Comparing Dayvigo to Other Insomnia Drugs Available in Nebraska

Price alone does not determine the right medication. Dayvigo belongs to the DORA class, which works differently from older insomnia drugs.

Generic zolpidem (immediate-release) costs $5 to $15 per month at Nebraska pharmacies and is the cheapest option. It acts on GABA-A receptors and is effective for sleep onset but less so for sleep maintenance. The FDA has issued warnings about complex sleep behaviors (sleepwalking, sleep-driving) associated with Z-drugs, leading to a boxed warning added in 2019 [6].

Generic suvorexant became available in 2023 and typically costs $30 to $60 per month in Nebraska. As a first-generation DORA, it shares the orexin-blocking mechanism with lemborexant but has a longer half-life (approximately 12 hours vs. lemborexant's 17 to 19 hours for the active moiety, though lemborexant's effective half-life at the receptor is considered functionally shorter based on clinical wakefulness data).

In the SUNRISE-1 trial, lemborexant 10 mg reduced wake after sleep onset (WASO) by 20.2 minutes more than placebo at the one-month endpoint (P<0.001), and by 10.5 minutes more than zolpidem ER 6.25 mg [2]. The sleep-onset benefit (latency to persistent sleep) was also significantly better for both lemborexant doses compared with placebo.

Dr. Andrew Krystal, who served as a principal investigator on the SUNRISE program, stated that "dual orexin receptor antagonists represent a mechanistically distinct approach to insomnia that avoids the GABA-mediated cognitive and motor side effects that concern many clinicians and patients."

Trazodone, prescribed off-label for insomnia, runs $4 to $10 per month and remains the most commonly prescribed insomnia medication in the U.S. It lacks strong RCT evidence for insomnia at the low doses typically used (25 to 100 mg), and the AASM guideline does not recommend trazodone for chronic insomnia disorder [3].

How to Get the Lowest Price for Dayvigo in Nebraska

A step-by-step approach can cut your Dayvigo cost significantly.

Step 1: Check your insurance formulary. Call the number on the back of your card and ask whether Dayvigo is covered, what tier it sits on, and what the prior authorization requirements are. If your plan covers it at Tier 3, your copay may be $50 to $80 before applying the Eisai savings card.

Step 2: Apply the Eisai savings card. If commercially insured, enroll in the savings program. This can reduce your remaining copay to $0. The savings card does not apply to the deductible phase of HDHPs, but it does apply once the deductible is satisfied.

Step 3: Compare pharmacy prices. Call at least three Nebraska pharmacies (one chain, one independent, one mail-order) and ask for the cash price for 30 tablets of Dayvigo 5 mg or 10 mg. The range across the state can vary by $40 or more.

Step 4: Ask about 90-day fills. Some insurers and pharmacies offer a lower per-unit cost for 90-day supplies. If your prescriber writes for a 90-day quantity, the total cost may be 20% to 25% less than three separate 30-day fills.

Step 5: Consider compounded lemborexant. If brand Dayvigo remains too expensive and your prescriber is comfortable with a compounded formulation, contact a licensed 503A pharmacy in Nebraska for pricing.

The NIH's National Heart, Lung, and Blood Institute emphasizes that untreated chronic insomnia increases cardiovascular risk, depression incidence, and workplace accidents, so cost should not be the sole barrier to treatment [7].

Safety Considerations Specific to Nebraska Prescribing

Dayvigo is classified as Schedule IV under the Controlled Substances Act. Nebraska law requires electronic prescribing for all controlled substances (the state's EPCS mandate has been in effect since 2024). Your prescriber must send the Dayvigo prescription electronically to the pharmacy. Paper prescriptions for Schedule IV drugs are no longer accepted at Nebraska pharmacies except in documented emergency situations.

The most common adverse effects in clinical trials were somnolence (reported in 10% of patients on lemborexant 10 mg vs. 1% placebo), headache, and abnormal dreams [1]. Sleep paralysis occurred in approximately 1% of patients on the 10 mg dose. The FDA label warns against use with strong CYP3A inhibitors, which increase lemborexant exposure [1].

For patients using lemborexant alongside GLP-1 receptor agonists or testosterone therapy, no pharmacokinetic interactions have been identified in the FDA labeling. Semaglutide, tirzepatide, and testosterone cypionate do not inhibit or induce CYP3A, the primary metabolic pathway for lemborexant.

The recommended starting dose is 5 mg taken once nightly, no more than 7 hours before planned waking. The dose can be increased to 10 mg if 5 mg is well tolerated but insufficiently effective.